drugset / Trial / NCT02664753

L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury

NCT02664753 ↗

Phase 3 Terminated 254 enrolled Nîmes University Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to compare 28 day mortality rates between septic shock patients with acute renal insufficiency treated via L-Carnitine (as an adjunct therapy) versus a similar group of patients not receiving L-Carnitine adjunct therapy.

Timeline

Start
2018-03-05
Primary completion
2024-12-04
Completion
2024-12-04

Outcome

Outcome not reported

Stopped: “Exposure to serious adverse events related to the research (i.e., death), the mnts = 54% versus 58 deaths out of 121 patients = 48%).onitoring committee unanimously recommended discontinuation of the trial.”

Drugs

EvaluationDrugModalityDoseRoute
Subject L-carnitine Other / unclassified 2 g Intravenous
Subject L-carnitine Other / unclassified 3 g Intravenous